Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2025

May 19, 2025

31565_dirs_2025-05-19_f2079417-3d5b-4f93-a5b4-cfb14616be58.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-05-15

Reporting Person: Galvin Roy (President, Global Plasma & BC)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-15 Common Stock F 201 $69.38 Disposed 7500 Direct
2025-05-16 Common Stock F 257 $70.31 Disposed 7243 Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported as well as 328 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025.